Quantinno Capital Management LP Grows Position in Sabra Healthcare REIT, Inc. $SBRA

Key Points

• Quantinno Capital Management increased its Sabra Healthcare REIT position by 424.3% in the first quarter, reaching 155,086 shares valued at approximately $2.98 million. Institutional investors collectively own 99.4% of SBRA’s outstanding stock.
• Analyst sentiment remains moderately positive, with seven Buy and seven Hold ratings and a consensus price target of $22.25. Recent targets range from $19 to $25.
• Sabra reported quarterly revenue of $230.1 million, up 24.7% year over year, but missed EPS estimates. The company declared a $0.30 quarterly dividend, representing a 5.7% annualized yield.

Quantinno Capital Management LP lifted its position in shares of Sabra Healthcare REIT, Inc. (NASDAQ:SBRA - Free Report) by 424.3% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 155,086 shares of the real estate investment trust's stock after purchasing an additional 125,507 shares during the quarter. Quantinno Capital Management LP owned about 0.06% of Sabra Healthcare REIT worth $2,982,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Principal Financial Group Inc. raised its holdings in Sabra Healthcare REIT by 21.6% in the fourth quarter. Principal Financial Group Inc. now owns 24,953,351 shares of the real estate investment trust's stock valued at $472,617,000 after buying an additional 4,431,897 shares during the period. Lasalle Investment Management Securities LLC acquired a new stake in shares of Sabra Healthcare REIT in the fourth quarter worth $66,938,000. Norges Bank acquired a new stake in shares of Sabra Healthcare REIT in the fourth quarter worth $57,945,000. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Sabra Healthcare REIT by 1,019.8% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,005,374 shares of the real estate investment trust's stock valued at $56,922,000 after acquiring an additional 2,736,993 shares during the period. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Sabra Healthcare REIT in the 2nd quarter valued at $49,955,000. Institutional investors and hedge funds own 99.40% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SBRA. Weiss Ratings lowered shares of Sabra Healthcare REIT from a "buy (b)" rating to a "hold (c+)" rating in a report on Tuesday. Citizens Jmp increased their price target on Sabra Healthcare REIT from $23.00 to $25.00 and gave the company a "market outperform" rating in a report on Wednesday, July 22nd. Cantor Fitzgerald raised their price objective on Sabra Healthcare REIT from $21.00 to $22.00 and gave the company a "neutral" rating in a research report on Monday, May 11th. Scotiabank decreased their target price on Sabra Healthcare REIT from $22.00 to $19.00 and set a "sector perform" rating for the company in a research report on Thursday, June 18th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Sabra Healthcare REIT in a research note on Wednesday, July 22nd. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $22.25.

Sabra Healthcare REIT Price Performance

SBRA opened at $21.04 on Friday. Sabra Healthcare REIT, Inc. has a twelve month low of $17.17 and a twelve month high of $22.77. The firm has a market cap of $5.37 billion, a price-to-earnings ratio of 80.93, a PEG ratio of 1.63 and a beta of 0.64. The company has a current ratio of 3.07, a quick ratio of 4.72 and a debt-to-equity ratio of 0.95. The company has a fifty day simple moving average of $19.82 and a 200 day simple moving average of $19.98.

Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The real estate investment trust reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.27). The firm had revenue of $230.11 million during the quarter, compared to analyst estimates of $219.39 million. Sabra Healthcare REIT had a return on equity of 2.34% and a net margin of 7.61%.The business's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.38 EPS. Equities research analysts expect that Sabra Healthcare REIT, Inc. will post 1.51 EPS for the current fiscal year.

Sabra Healthcare REIT Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 5.7%. The ex-dividend date of this dividend is Friday, August 14th. Sabra Healthcare REIT's payout ratio is presently 461.54%.

Sabra Healthcare REIT Company Profile

Sabra Healthcare REIT, Inc NASDAQ: SBRA is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra's tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source